Compare CWEN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWEN | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | CWEN | ACAD |
|---|---|---|
| Price | $39.76 | $22.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $42.00 | $30.55 |
| AVG Volume (30 Days) | 702.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $16.38 | $18.80 |
| Revenue Next Year | $8.48 | $11.70 |
| P/E Ratio | $17.06 | ★ $9.61 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $27.67 | $14.18 |
| 52 Week High | $41.51 | $28.35 |
| Indicator | CWEN | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 49.63 |
| Support Level | $36.30 | $20.81 |
| Resistance Level | $40.11 | $22.03 |
| Average True Range (ATR) | 1.11 | 0.62 |
| MACD | -0.19 | 0.07 |
| Stochastic Oscillator | 56.08 | 52.89 |
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.